Exploring mechanisms of resistance to HIV in people with sickle cell disease

April 08, 2020

A new analysis supports prior reports that people with sickle cell disease have lower rates of human immunodeficiency virus (HIV) infection, but follow-up cell studies did not reveal a mechanism to explain the reduced risk. Shannon Kelly of Vitalant Research Institute in San Francisco, CA, and colleagues presented these findings in the open-access journal PLOS ONE on April 8, 2020.

A number of epidemiological reports have suggested that people with sickle cell disease experience low rates of HIV infection compared to the general population. However, the mechanisms behind this reduced risk remain unclear. To better understand the reduced risk, Kelly and colleagues conducted a two-part investigation. First, they ran a new statistical analysis of data from a previous study of people with conditions characterized by low red blood cell count, including sickle cell disease. They found that those with sickle cell disease did indeed experience lower rates of HIV infection.

Next, the researchers conducted a lab study of immune system cells isolated from blood samples from HIV-negative patients with or without sickle cell disease. They hypothesized that lower risk of HIV infection might be related to molecular characteristics of immune system cells known as CD4+ T cells.

The lab studies did find that CD4+ T cells from people with sickle cell disease had lower levels of CCR5, a key protein involved in HIV infection. These cells also had lower levels of the protein CCR7 and higher levels of the protein CD4. However, further experiments showed that the cells were no less susceptible to HIV infection than were CD4+ T cells from people without sickle cell disease.

These findings lend further support to the idea that people with sickle cell disease are less likely to be infected with HIV. However, further research is needed to determine whether the molecular differences uncovered in this study are related to this lower risk, or if other mechanisms are at play.

The authors add: "The Transfusion Safety Study which was conducted in 1985-1993 was retrospectively reviewed to compare HIV status between sickle cell disease (SCD) and other congenital anemia participants who were routinely exposed to blood products during the high-risk period before HIV screening implementation. SCD participants demonstrated a lower risk of HIV acquisition compared to non-SCD participants."
-end-
Citation: Kelly S, Jacobs ES, Stone M, Keating SM, Lee T-H, Chafets D, et al. (2019) Influence of sickle cell disease on susceptibility to HIV infection. PLoS ONE 14(11): e0218880. https://doi.org/10.1371/journal.pone.0218880

Funding: This work was funded by the National Heart Lung and Blood Institute (HHSN268201100007I Task Order 4). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

In your coverage please use this URL to provide access to the freely available article in PLOS ONE:https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0218880

PLOS

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.